Please login to the form below
Cannabis
This page shows the latest Cannabis news and features for those working in and with pharma, biotech and healthcare.
FDA clears SK Life Science’s anti-epileptic drug Xcopri
This includes GW Pharma’s Epidyolex, which is the first medicine based on a highly-purified, plant derived CBD, which lacks the high associated with cannabis or marijuana.
Latest news
-
NICE backs first cannabis-based drugs, both from GW Pharma
for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS”. ... didn’t recommend any cannabis-based treatments for pain” associated with the disease.
-
GW Pharma’s Epidyolex gets EU approval for severe epilepsy
It is the first medicine based on highly-purified, plant-derived cannabidiol (CBD), which lacks the high associated with cannabis or marijuana. ... cannabis oil products confiscated by customs on entry to the UK even with private prescriptions.
-
Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
The drug has been approved in the US since June 2018 (where it is known as Epidiolex) and where it became the first ever cannabis-derived product to gain FDA approval.
-
CHMP backs Bayer’s tumour-agnostic drug Vitrakvi
epilepsy. The drug was also approved in the US last year as Epidiolex, becoming the first ever prescription medicine derived from cannabis.
-
Intec sounds a sad note as Accordion Parkinson’s trial fails
The emergence of the cannabis product sector in light of relaxed rules in countries like the UK, Germany and Canada is also significant, with analysts saying there could be “considerable upside”
More from news
Approximately 3 fully matching, plus 62 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
3. Epidiolex – leading the flowering therapeutic cannabinoid market. The last 12 months have seen a huge growth in interest in the therapeutic potential of cannabis, with authorities now allowing regulated access ... GW Pharma gained an historic
-
Death by Numbers
The obvious solution to the brief was an ingredient story - Sativex is derived from cannabis.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Blockchain for Tracking and Validating Medical Cannabis
Robert Galarza, CEO of TruTrace Technologies, Inc., dives into the use of blockchain technology for verifying medical cannabis products and protecting intellectual property. ... He also shares his leadership tips and predictions for the future of the
-
Advancing the Scientific Understanding of Medical Cannabis Through Real-Time User Data
David Berg, President and CTO of Strainprint, explores the current state of the medical cannabis industry in Canada and overseas and how Strainprint is bringing innovation to the industry.
-
War on drugs: the use of controlled substances in medicine
And not forgetting cannabis, a drug which is booming and infiltrating all areas of health and wellness including skincare and beauty treatments. ... It has shown promise in mental health conditions, skin conditions and a cannabis-based medicine is now
More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
